BioPorto Diagnostics – Public Rights Issue of 12 mUSD

Public Rights Issue of 12 million USD to BioPorto Diagnostics.

Tofte & Company has been involved in this transaction from day one, and we are proud to say so!

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Their pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. They sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock exchange.